Circulation:心力衰竭和心房颤动患者中控制节奏重要还是与速率控制重要?

2022-03-29 网络 网络

房颤消融是一种治疗始于心脏上腔(心房)的心跳不规律(心律不齐)的手术。

房颤消融是一种治疗始于心脏上腔(心房)的心跳不规律(心律不齐)的手术。这是心脏消融术的一种,通过给心脏上的组织留下疤痕或造成损坏来破坏导致心律失常的错误电信号。如果用于控制心律不齐的药物或其他干预措施无效,可以采用房颤消融。

心房颤动(AF)和心力衰竭(HF)经常并存,治疗起来具有挑战性。基于药物的房颤节律控制还没有被证明优于速率控制。将基于消融的节律控制与速率控制进行比较,以评估HF和房颤患者的临床结果是否可以得到改善,结果发表在Circulation杂志上。

这是一项多中心、开放标签的试验,使用中央裁决委员会进行盲法结果评估。高负担的阵发性(6个月内>4次发作)或持续性(持续时间<3年)房颤、纽约心脏协会(NYHA)II-III级HF和NT-proBNP升高的患者被随机分配到基于消融的节奏控制或速率控制。主要结果是全因死亡和所有HF事件的综合,至少随访两年。次要结果包括左心室射血分数(LVEF)、六分钟步行测试和NT-proBNP。

从2011年12月1日至2018年1月20日,411名患者被随机分配到基于消融的节奏控制(n=214)或速率控制(n=197)。主要结果发生在基于消融的节奏控制组的50名(23.4%)患者和速率控制组的64名(32.5%)患者身上。总的来说,节奏控制组主要结局事件风险降低29%(HR=0.71,95% CI(0.49,1.03),P=0.066)。

同时,消融组的LVEF增加(10.1±1.2% vs 3.8±1.2%,p=0.017);六分钟步行距离改善(44.9±9.1米 27.5±9.7米,p=0.025),NT-proBNP显示下降(平均变化-77.1% vs -39.2%,p<0.0001)。MLHFQ在基于消融的心律控制组有更大的改善(LSMD为-5.4,95%CI(-10.5,-0.3),p=0.0036),AFEQT评分也是如此(LSMD为6.2,95%CI(1.7,10.7),p=0.0005)。

综上,在高负荷房颤和HF患者中,基于消融的节律控制与速率控制在全因死亡率或HF事件方面没有统计学差异,然而,基于消融的节律控制比速率控制的结果有改善的非显著趋势。

 

参考文献:

Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. https://doi.org/10.1161/CIRCULATIONAHA.121.057095. Circulation. 2022;0

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1814281, encodeId=42d7181428135, content=<a href='/topic/show?id=7d719495256' target=_blank style='color:#2F92EE;'>#速率控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94952, encryptionId=7d719495256, topicName=速率控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Aug 25 18:23:11 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206865, encodeId=3edc120686554, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61956398536, createdName=ms7000000387339206, createdTime=Tue Mar 29 11:53:02 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206820, encodeId=3f391206820df, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151012/IMG561BAA9D6BE6E9457.jpg, createdBy=e2ea1655774, createdName=Lunar灰, createdTime=Tue Mar 29 09:24:40 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626989, encodeId=010c1626989a4, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Mar 28 08:23:11 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-08-25 chendoc242
  2. [GetPortalCommentsPageByObjectIdResponse(id=1814281, encodeId=42d7181428135, content=<a href='/topic/show?id=7d719495256' target=_blank style='color:#2F92EE;'>#速率控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94952, encryptionId=7d719495256, topicName=速率控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Aug 25 18:23:11 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206865, encodeId=3edc120686554, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61956398536, createdName=ms7000000387339206, createdTime=Tue Mar 29 11:53:02 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206820, encodeId=3f391206820df, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151012/IMG561BAA9D6BE6E9457.jpg, createdBy=e2ea1655774, createdName=Lunar灰, createdTime=Tue Mar 29 09:24:40 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626989, encodeId=010c1626989a4, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Mar 28 08:23:11 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-03-29 ms7000000387339206

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1814281, encodeId=42d7181428135, content=<a href='/topic/show?id=7d719495256' target=_blank style='color:#2F92EE;'>#速率控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94952, encryptionId=7d719495256, topicName=速率控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Aug 25 18:23:11 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206865, encodeId=3edc120686554, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61956398536, createdName=ms7000000387339206, createdTime=Tue Mar 29 11:53:02 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206820, encodeId=3f391206820df, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151012/IMG561BAA9D6BE6E9457.jpg, createdBy=e2ea1655774, createdName=Lunar灰, createdTime=Tue Mar 29 09:24:40 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626989, encodeId=010c1626989a4, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Mar 28 08:23:11 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-03-29 Lunar灰

    👍👍👍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1814281, encodeId=42d7181428135, content=<a href='/topic/show?id=7d719495256' target=_blank style='color:#2F92EE;'>#速率控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94952, encryptionId=7d719495256, topicName=速率控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Aug 25 18:23:11 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206865, encodeId=3edc120686554, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61956398536, createdName=ms7000000387339206, createdTime=Tue Mar 29 11:53:02 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206820, encodeId=3f391206820df, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151012/IMG561BAA9D6BE6E9457.jpg, createdBy=e2ea1655774, createdName=Lunar灰, createdTime=Tue Mar 29 09:24:40 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626989, encodeId=010c1626989a4, content=<a href='/topic/show?id=986a5101e46' target=_blank style='color:#2F92EE;'>#心房#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51017, encryptionId=986a5101e46, topicName=心房)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20ba21064884, createdName=sodoo, createdTime=Mon Mar 28 08:23:11 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-03-28 sodoo

    #心房#

    0

相关资讯

Interact Cardiovasc Thorac Surg:阜外医院郑哲发现房颤伴左房扩大,外科微创消融双房更有效!

治疗晚期阵发性房颤或持续性房颤,胸腔镜下双房消融(BA Lesion)比“盒式”(Box lesion)消融更有效,能减少房性快速心律失常复发。

JAHA:房颤患者颅内出血后抗栓治疗

OAC被推荐用于房颤和颅内出血患者,因为它们降低了IS的风险,而不会增加后续ICH的风险。推荐的非维生素K拮抗剂OAC优于华法林,因为它们具有生存优势。

JAHA:房颤患者抗凝治疗剂量不当与卒中严重程度和预后的关系

半数患有卒中的房颤患者接受了不适当的OAC治疗。与适当的VKA治疗相比,亚治疗性VKA与更严重的卒中严重程度和更高的死亡率相关。与适当剂量的DOAC相比,在调整后的模型中,剂量不足或过量的DOAC均与

Heart:智能手机光电容积描记法检测房颤的效果

PPG为心房颤动提供了一种无创、以患者为主导的筛查工具。然而,目前的证据仅限于高敏感性和特异性的小型、有偏见、低质量的研究。

Stroke:虚弱的房颤患者,抗凝治疗更有效,且NOAC可降低卒中、出血发生率和死亡率

近日,韩国延世大学医科大学附属Severance心血管医院心内科Daehoon Kim等人发表在Stroke上的一项研究中使用基于人群的队列,评估了口服抗凝剂 (OAC) 在虚弱的AF患者中的有效性。

JAHA:抗凝药物的使用剂量与房颤患者卒中严重程度和预后的相关性分析

近日,发表在J Am Heart Assoc杂志上的一项研究表明,约半数发生卒中的房颤(AF)患者接受了不当剂量的口服抗凝剂(OAC)治疗。

拓展阅读

European Radiology:射频消融治疗甲状旁腺功能亢进的疗效和安全性

甲状旁腺功能亢进会导致各种功能异常,包括肾结石、病理性骨折、骨质疏松、消化性溃疡病、胰腺炎、神经精神症状以及肌肉骨骼症状,因此需要进行治疗。

电子科技大学张坤教授团队Biomaterials:纳米医学解锁射频动力学疗法用于肝细胞癌不完全射频消融后重塑免疫抑制微环境

肝细胞癌射频消融存在不完全消融致肿瘤复发转移问题,电子科技大学与复旦大学团队合成 P@Fe SAZ,解锁射频动力疗法,经多手段验证其能产 ROS、杀伤癌细胞、重塑免疫环境及抗转移。

Nat Commun:中国学者揭示立体定向体部放射治疗(SBRT)在非侵入性肺动脉去神经术(PADN)中的创新应用

尽管本研究通过动物模型验证了SBRT在PADN中的潜力,但其临床应用仍需进一步探索。未来需要开展大规模的临床试验,以验证SBRT的长远安全性、最佳剂量方案以及与其他PH治疗方法的协同作用。

Radiology:微波与射频消融治疗良性甲状腺结节的价值及差异

微波消融(MWA)近年来已成为另一种常用的技术,由于其快速加热和更好的局部肿瘤控制的优点,在许多中心已取代RFA用于肝定向治疗肝细胞癌。

【论著】| 基于CT的影像组学诺模图预测结直肠癌肺转移射频消融后的局部肿瘤进展

本研究旨在构建基于影像组学的诺模图,从而预测CRC肺转移患者RFA治疗后的LTPFS。

European Radiology:射频消融治疗骨样骨瘤的回顾性评估

据报道,对疑似OO的活检诊断率从33%到75%不等,低于其他骨病变的活检诊断率。因此,必须决定是否要求病理科医师对标本进行快速准备和解释,是否在等待结果时延迟消融。